Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | USP5 | P45974 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273823 | 0.93 | CACNA1H (0.55) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3049521 | 0.91 | POLB (0.53) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3281479 | 0.91 | CACNA1H (0.59) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3275037 | 0.90 | TDP1 (0.50) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3054975 | 0.88 | KDM4E (0.57) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL13835112 | 0.87 | POLB (0.53) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3045528 | 0.87 | TDP1 (0.54) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3054976 | 0.86 | HTT (0.59) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL3054853 | 0.85 | POLB (0.52) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B | |
| SCHEMBL15103767 | 0.85 | HSD17B10 (0.50) | PTGDR2TDP1L3MBTL1CACNA1HCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-29 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
| EP-2076491-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-08 | — | — | EP | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008068540-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGDR2 225/4885TDP1 4167/4885L3MBTL1 1790/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | PTGDR2 233/4885TDP1 4198/4885L3MBTL1 1531/4885 |
| US-20100105686-A1 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | PTGDR2 244/4885TDP1 4005/4885L3MBTL1 1455/4885 |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | PTGDR2 195/4885TDP1 4124/4885L3MBTL1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.